Related Experiment Video
Updated: May 8, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Pulse corticosteroid therapy for alopecia areata in children: a retrospective study
Rivka Friedland1, Rotem Tal, Moshe Lapidoth
1Department of Dermatology, Rabin Medical Center, Petach Tikva, Israel.
Insights
Intravenous high-dose pulse corticosteroids show moderate effectiveness for pediatric alopecia areata, with relapse common. Shorter disease duration, younger age, and multifocal disease predict better outcomes.
Area of Science:
- Pediatric Dermatology
- Autoimmune Disorders
- Clinical Therapeutics
Background:
- Alopecia areata commonly affects children and adolescents.
- Systemic steroids, particularly high-dose pulse infusions, are a frequent treatment modality.
- Identifying predictors of treatment success is crucial for optimizing patient care.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous high-dose pulse corticosteroids in pediatric alopecia areata.
- To determine prognostic factors associated with successful treatment outcomes.
- To assess the long-term relapse rates following treatment.
Main Methods:
- A retrospective analysis of 24 children with alopecia areata treated between 2001-2008.
- Patients received intravenous methylprednisolone (8 mg/kg) over 3 consecutive days monthly.
- Data on treatment response, side effects, and prognostic factors were collected.
Main Results:
- 38% achieved complete response, 29% partial response, and 33% no response after a mean of 5.65 courses.
- 81% of responders relapsed within 9.5 months.
- Positive prognostic factors included short disease duration (≤6 months), younger age at onset (<10 years), and multifocal disease.
Conclusions:
- Pulse corticosteroid therapy offers a viable treatment option for pediatric alopecia areata, though relapse is frequent.
- Careful patient selection based on prognostic factors can maximize treatment benefits.
- Further research into long-term management strategies is warranted.
Background/Objective:
Alopecia areata may occur at any age, though usually before the age of 20 years. Treatment often consists of systemic steroids administered as high-dose bolus infusions. This study sought to investigate the effectiveness and side effects of intravenous high-dose pulse corticosteroids in children with alopecia areata and to identify prognostic factors for successful treatment.
Methods:
Patients treated with pulse corticosteroids for alopecia areata in 2001-2008 at the day care unit of a tertiary pediatric medical center were identified by computerized file search and clinical treatment and outcome data were collected.
Results:
The sample included 24 children (16 female, 8 male) with a mean age of 8.5 ± 4.6 years at diagnosis; 8 (33%) had multifocal disease,10 (42%) multifocal disease with ophiasis, 4 (17%) alopecia totalis and 2 (8%) alopecia universalis. Nail involvement was noted in 9 patients (38%). Mean duration of disease was 22 ± 27 months. Patients were treated with 8 mg/kg body weight intravenous methylprednisolone on 3 consecutive days at 1-month intervals. After a mean of 5.65 ± 1.95 courses, 9 patients (38%) had a complete response, 7 (29%) a partial response and 8 (33%) no response. Of the 16 responders, 13 (81%) relapsed at 9.5 ± 12 months after the last course; 3 patients had side effects, none of which were severe. Three positive prognostic factors were identified: short disease duration (≤6 months), younger age at disease onset (<10 years) and multifocal disease (as opposed to severe, diffuse variants).
Conclusions:
Careful patient selection is necessary to achieve maximal benefit from pulse corticosteroid treatment for alopecia areata in children.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
COPD: Management Using Bronchodilators and Corticosteroids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cushing Syndrome II: Pathophysiology
Cushing Syndrome I: Introduction

